[ad_1]

Bristol-Myers Squibb announced data presentations at the American College of Cardiology (ACC) Annual Scientific Sessions and Expo held April 6-8, 2024 in Atlanta, Georgia. Data included robust safety and clinical findings for mabacamten (Camjos). Adherence to risk assessment and mitigation strategy programs.1

Image credit: Artem – Stock.adobe.com

“The therapeutic benefits are [mavacamten] In real-world clinical practice, the data at ACC further underlines the importance of this medical innovation, which is based on an established clinical program and is the first and only approved cardiac myosin inhibitor. . Thousands of patients have been treated around the world, [mavacamten] Roland Chen, M.D., senior vice president and head of development, immunology, cardiovascular and neurology at Bristol-Myers Squibb, said in a press release. “In addition to showcasing a growing body of real-world evidence and safety data, [mavacamten] At ACC, we look forward to highlighting additional data from our cardiovascular portfolio. This also includes an analysis of the actual cardiovascular clinical impact. [apixaban (Eliquis)]”1

According to the American Heart Association, approximately 931,578 deaths in the United States were due to cardiovascular disease in 2021. Additionally, approximately 48.6% of U.S. adults had some type of cardiovascular disease between 2017 and 2020.2

In one of the mavacamten poster sessions, approximately 1% of 1524 patients reported clinical heart failure requiring hospitalization, and 2.8% had a left ventricular ejection fraction (LVEF) of 50 at 10 months after treatment. The results showed that they reported a decrease of less than %. According to a press release, launch data. This data was also consistent with the safety profile of mavacamten in clinical practice.1

Furthermore, in another study, a real-world analysis showed that 96% of 53 people treated with mavacamten had improved cardiovascular symptoms, and 49% had one or more New York Heart Association classes at 24 weeks. It was shown that there was an improvement. Additionally, data showed that resting and Valsalva left ventricular outflow tract (LVOT) gradients decreased during the first 4 weeks of treatment, with a statistically significant decrease from baseline at 24 weeks, according to a press release. showed that. The researchers reported that no one had to stop treatment due to decreased LVEF or other adverse events. However, two patients temporarily discontinued the drug because their Valsalva LVOT slope was less than 20 mmHg during treatment, according to a press release.1

Important points

  1. Real-world data suggest a favorable safety profile with low hospitalization rates for heart failure (1%) and reduction in ejection fraction below 50% (2.8%) after 10 months of use.
  2. Another study showed improvement in cardiovascular symptoms (96%) and functional class (49%) in patients treated with mavacamten for 24 weeks.
  3. Mavacamten is the first FDA-approved cardiac myosin inhibitor and offers a new treatment option for HCM.

For apixaban, real-world data is available for patients with non-valvular atrial fibrillation (NVAD) and Medicare who were previously treated with warfarin and switched to a direct oral anticoagulant (DOAC) including apixaban, dabigatran, or rivaroxaban. It was from a patient. According to a press release, the data showed that people receiving apixaban had a significantly lower risk of stroke or systemic embolism and major bleeding than those receiving dabigatran or rivaroxaban. This analysis shows the incidence of stroke or systemic embolism and major bleeding associated with switching from warfarin to another DOAC in NVAD patients receiving Medicare.1

reference
  1. Bristol-Myers Squibb will present data at the 2024 American College of Cardiology Annual Scientific Sessions, reinforcing extensive evidence in clinical and real-world settings across its cardiovascular portfolio. news release. Bristol-Myers Squibb Company. March 25, 2024. Accessed March 27, 2024. https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-to-Present-Data-at-the-American-College-of -Cardiology-Annual-Scientific-Session-2024- Extensive evidence reinforcement in Clinical-and-Real-World-Settings-Across-Cardiovascular-Portfolio/default.aspx
  2. Martin SS, Aday AW, Almarzooq ZI, et al. On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2024: American Heart Association report on U.S. and global data. Circulation. 2024.doi:10.1161/CIR.0000000000001209

[ad_2]

Source link